{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:56Z","timestamp":1786984316148,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014935","name":"BioCryst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014935","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.anai.2025.06.004","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T11:07:37Z","timestamp":1749294457000},"page":"311-319.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema"],"prefix":"10.1016","volume":"135","author":[{"given":"Henriette","family":"Farkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonny G.","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Stobiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Ayg\u00f6ren-P\u00fcrs\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161","family":"Jese\u0148\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorena","family":"Kiani-Alikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Kinaciyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avner","family":"Reshef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Iocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas T.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anai.2025.06.004_bib0001","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","article-title":"Hereditary angioedema: diagnosis, clinical implications, and pathophysiology","volume":"40","author":"Sinnathamby","year":"2023","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.anai.2025.06.004_bib0002","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.06.004_bib0003","doi-asserted-by":"crossref","first-page":"S03","DOI":"10.2500\/aap.2020.41.200040","article-title":"Definition and classification of hereditary angioedema","volume":"41","author":"Proper","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.anai.2025.06.004_bib0004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1213\/ANE.0000000000004710","article-title":"Perioperative management of patients with hereditary angioedema with special considerations for cardiopulmonary bypass","volume":"131","author":"Tanaka","year":"2020","journal-title":"Anesth Analg"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.06.004_bib0005","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.2500\/aap.2020.41.200065","article-title":"Clinical presentation of hereditary angioedema","volume":"41","author":"Azmy","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"9","key":"10.1016\/j.anai.2025.06.004_bib0006","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1177\/00099228231155703","article-title":"A comprehensive management approach in pediatric and adolescent patients with hereditary angioedema","volume":"62","author":"Tachdjian","year":"2023","journal-title":"Clin Pediatr (Phila)"},{"issue":"7","key":"10.1016\/j.anai.2025.06.004_bib0007","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jaip.2022.04.030","article-title":"Investigation of mortality of hereditary angioedema in a reference center in Brazil","volume":"10","author":"Minafra","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.06.004_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100758","article-title":"A narrative review of recent literature of the quality of life in hereditary angioedema patients","volume":"16","author":"Chong-Neto","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"suppl 1","key":"10.1016\/j.anai.2025.06.004_bib0009","doi-asserted-by":"crossref","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: epidemiology and burden of disease","volume":"41","author":"Lumry","year":"2020","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"10.1016\/j.anai.2025.06.004_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: A consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2025.06.004_bib0011","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.06.004_bib0012","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jaci.2021.05.016","article-title":"Consensus on treatment goals in hereditary angioedema: a global Delphi initiative","volume":"148","author":"Maurer","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.06.004_bib0013","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/JAA.S396338","article-title":"A review of randomized controlled trials of hereditary angioedema long-term prophylaxis with C1 inhibitor replacement therapy: alleviation of disease symptoms is achievable","volume":"16","author":"Longhurst","year":"2023","journal-title":"J Asthma Allergy"},{"issue":"3","key":"10.1016\/j.anai.2025.06.004_bib0014","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jaip.2021.11.011","article-title":"Specific targeting of plasma kallikrein for treatment of hereditary angioedema: a revolutionary decade","volume":"10","author":"Busse","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2025.06.004_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18176\/jiaci.0653","article-title":"Treatment of hereditary angioedema","volume":"31","author":"Caballero","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.004_bib0016","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13223-021-00603-9","article-title":"Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema","volume":"17","author":"Gower","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.06.004_bib0017","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2500\/aap.2021.42.210025","article-title":"Patient perspectives on the treatment burden of injectable medication for hereditary angioedema","volume":"42","author":"Radojicic","year":"2021","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"10.1016\/j.anai.2025.06.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253048","article-title":"The prevalence and evidence-based management of needle fear in adults with chronic disease: a scoping review","volume":"16","author":"Duncanson","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.anai.2025.06.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12391","article-title":"Advent of oral medications for the treatment of hereditary angioedema","volume":"14","author":"Valerieva","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.anai.2025.06.004_bib0020","unstructured":"US Food and Drug Administration. Center for Biologics Evaluation and Research (CBER). The voice of the patient: hereditary angioedema. Accessed December 3, 2024. Available at: https:\/\/www.fda.gov\/files\/about%20fda\/published\/The-Voice-of-the-Patient\u2014Hereditary-Angioedema.pdf"},{"key":"10.1016\/j.anai.2025.06.004_bib0021","unstructured":"BioCryst Pharmaceuticals Inc. ORLADEYO\u2122 (berotralstat) capsules, for oral use \u2013 prescribing information. Accessed February 25, 2025. Available at: https:\/\/www.biocryst.com\/wp-content\/uploads\/ORLADEYO_USPI.pdf"},{"issue":"3","key":"10.1016\/j.anai.2025.06.004_bib0022","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40265-021-01475-4","article-title":"First approval","volume":"81","author":"Berotralstat","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.anai.2025.06.004_bib0023","unstructured":"BioCryst Ireland Limited. Orladeyo 150 mg hard capsules \u2013 summary of product characteristics. Accessed February 25, 2025. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orladeyo-epar-product-information_en.pdf"},{"issue":"1","key":"10.1016\/j.anai.2025.06.004_bib0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.06.004_bib0025","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jaip.2021.03.057","article-title":"Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2)","volume":"9","author":"Wedner","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2025.06.004_bib0026","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaip.2023.12.019","article-title":"Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: the open-label extension of the APeX-2 randomized trial","volume":"12","author":"Kiani-Alikhan","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2025.06.004_bib0027","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/all.14670","article-title":"Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial","volume":"76","author":"Ohsawa","year":"2021","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2025.06.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2024.100882","article-title":"Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: parts 2 and 3 of the randomized APeX-J phase III trial","volume":"17","author":"Honda","year":"2024","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.anai.2025.06.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12035","article-title":"Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study","volume":"11","author":"Farkas","year":"2021","journal-title":"Clin Transl Allergy"},{"issue":"10","key":"10.1016\/j.anai.2025.06.004_bib0030","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/all.12007","article-title":"Development and construct validation of the angioedema quality of life questionnaire","volume":"67","author":"Weller","year":"2012","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.anai.2025.06.004_bib0031","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"issue":"11","key":"10.1016\/j.anai.2025.06.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100841","article-title":"Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: a subset analysis of the APeX-S trial","volume":"16","author":"Peter","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"3","key":"10.1016\/j.anai.2025.06.004_bib0033","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.anai.2020.10.009","article-title":"Current medical management of hereditary angioedema: follow-up survey of US physicians","volume":"126","author":"Riedl","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.06.004_bib0034","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"Us HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2025.06.004_bib0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.anai.2023.11.016","article-title":"Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat","volume":"132","author":"Riedl","year":"2024","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625002790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625002790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T15:23:27Z","timestamp":1756740207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625002790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1081120625002790"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.004","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}